President Donald Trump May 30 signed the “Right to Try” bill into law, making it possible for terminally ill patients to bypass FDA to gain access to experimental drugs.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
